IMAB
I-MAB Sponsored ADR · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website i-mabbiopharma.com
- Employees(FY) -
- ISIN US44975P1030
Performance
+1.13%
1W
-2.19%
1M
-10.5%
3M
+11.18%
6M
-5.79%
YTD
-40.73%
1Y
Profile
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Technical Analysis of IMAB 2024-05-03
Overview:
In analyzing the technical indicators for IMAB stock over the last 5 days, we will delve into the trends, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible future stock price movement. By examining these key aspects, we aim to offer valuable insights and recommendations for potential investo...
Recent News & Updates
- 2024-05-02 00:00
Q1 2024 Summit Therapeutics Inc Earnings Call(Yahoo Finance)
- 2024-04-29 19:00
I-MAB Filed 2023 Annual Report on Form 20-F(Prnewswire)
- 2024-04-04 19:00
- 2024-04-02 04:01
- 2024-03-14 05:00
- 2024-03-06 21:03
- 2024-02-20 12:56
Q4 2023 Summit Therapeutics Inc Earnings Call(Yahoo Finance)
- 2024-02-06 19:28
- 2024-02-06 17:29
- 2024-02-06 17:00
- 2023-11-05 19:00
- 2023-11-01 20:00
- 2023-10-31 20:00
- 2023-10-15 20:00
- 2023-10-09 20:00
- 2023-10-05 05:17
Ray Dalio on Potential US-China War and Rise of China(Yahoo Finance)
- 2023-09-22 05:03
- 2023-09-04 20:00
- 2023-08-17 22:55
I-Mab (NASDAQ:IMAB) Q2 2023 Earnings Call Transcript(Yahoo Finance)
- 2023-08-17 10:30
Half Year 2023 I-Mab Earnings Call(Yahoo Finance)
- 2023-08-16 18:00
- 2023-08-16 17:25
Analyst Report: I-Mab(Yahoo Finance)
- 2023-08-07 20:00
- 2023-07-07 06:35
- 2023-07-04 20:00
- 2023-06-21 20:00
I-Mab Announces the Appointment of Raj Kannan as CEO(Yahoo Finance)
- 2023-06-10 22:31
- 2023-05-25 22:00
- 2023-05-25 05:01
- 2023-04-30 20:00
I-MAB Filed 2022 Annual Report on Form 20-F(Yahoo Finance)
Page 1 of 4
previousnext